Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Beta-Blocker Treatment Did Not Reduce Exacerbation Risk in COPD

Key clinical point: Beta-blocker treatment did not reduce the risk of exacerbations and death in patients with moderate to severe COPD.

Major finding: Median time to the first exacerbation was 202 days (95% CI, 162-282) in the metoprolol group and 222 days (95% CI, 189-295) in the placebo group.

Study details: A prospective, randomized trial of 532 patients with COPD who received either a beta-blocker or placebo.

Disclosures: The study was supported by a grant from the Department of Defense. The authors reported numerous potential conflicts of interest, including receiving grants, personal fees and research funds from various pharmaceutical companies and government entities.


Dransfield MT et al. CHEST 2019. 2019 Oct 20. doi: 10.1056/NEJMoa1908142.